Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace

被引：0
作者：
Beck M. [1 ,2 ]
Velten M. [1 ]
Rybarczyk-Vigouret M.-C. [2 ]
Covassin J. [3 ]
Sordet C. [4 ]
Michel B. [2 ,5 ]
机构：
[1] Laboratoire d’épidémiologie et de santé publique-EA 3430, Faculté de Médecine, Université de Strasbourg, Strasbourg Cedex
[2] OMEDIT Alsace, Agence Régionale de Santé d’Alsace, 14, rue du Maréchal Juin, Strasbourg Cedex
[3] Direction Régionale du Service Médical d’Alsace-Moselle, Strasbourg Cedex
[4] Service de rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg Cedex
[5] Service de Pharmacie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Laboratoire HuManiS-EA 7308, Faculté de Pharmacie, Université de Strasbourg, Strasbourg Cedex
来源：
Drugs - Real World Outcomes | 2015年 / 2卷 / 3期
关键词：
Rheumatoid Arthritis; Infliximab; Rheumatoid Arthritis Patient; Etanercept; Adalimumab;
D O I：
10.1007/s40801-015-0030-9
中图分类号：
学科分类号：
摘要：
Background: The economic burden linked to rheumatoid arthritis (RA) has greatly increased since the inclusion of biotherapies in the therapeutic arsenal. Objectives: This study aimed first to look at the breakdown of the rheumatoid arthritis patients on biotherapy in Alsace, France, in 2012, then to evaluate the annual cost per treated patient for each management pathway: inpatient care with intravenous biotherapies and/or outpatient care through the use of subcutaneous drugs, and finally to conduct a cost comparison with a focus on infliximab, adalimumab and etanercept. Methods: This observational study was conducted in Alsace using 2012 health claims data from the DCIR (Données de Consommation Inter Régime) and PMSI (Programme de Médicalisation des Systèmes d’Information) databases, taking into account direct medical and non-medical costs in a real-life setting and from a National Health Insurance perspective. Results: There were 5702 RA patients, i.e. 0.31 % of the Alsace population in 2012, including 1075 subjects (18.85 %) receiving biotherapy treatment. The most frequently prescribed biotherapies were etanercept and adalimumab. The estimated overall cost of care of these 5702 patients was €30.3 million, with about 50 % for the care of the 18.85 % patients on biotherapy. Average costs for inpatient, outpatient and mixed care ranged from €14,197 to €16,873 per patient per year. Annual average cost for management of a single RA patient with infliximab was significantly higher than with adalimumab and etanercept: €16,480 versus €14,116 and €14,338, respectively. Conclusion: These findings confirm the trends of initial modelling approaches and quantify the cost difference between various biotherapy management pathways. © 2015, The Author(s).
引用
收藏
页码：205 / 215
页数：10
相关论文
共 26 条
  • [1] Smolen J.S., Landewe R., Breedveld F.C., Et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 3, pp. 492-509, (2014)
  • [2] Management of early rheumatoid arthritis, A national clinical guideline, 123, (2011)
  • [3] American College of Rheumatology, Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Et al., 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis, Arthritis Care Res, 64, 5, pp. 625-639, (2012)
  • [4] Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, London: NICE, (2010)
  • [5] Update of the clinical practice guideline for the management of rheumatoid arthritis in Spain, Madrid: Spanish Society of Rheumatology, (2007)
  • [6] Jonsson B., Kobelt G., Smolen J., The burden of rheumatoid arthritis and access to treatment: uptake of new therapies, Eur J Health Econ, 8, pp. S61-S86, (2008)
  • [7] Kavanaugh A., Economic consequences of established rheumatoid arthritis and its treatment, Best Pract Res Clin Rheumatol, 21, 5, pp. 929-942, (2007)
  • [8] Modena V., Bianchi G., Roccatello D., Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?, Autoimmun Rev, 12, pp. 835-838, (2013)
  • [9] Or Z., Implementation of DRG Payment in France: Issues and recent developments, Health Policy, 117, pp. 146-150, (2014)
  • [10] Maravic M., Economic impact of rheumatoid arthritis (RA) biotherapies in France, Jt Bone Spine, 77, pp. 319-324, (2010)
123